1. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients;Rosenberg, S.A.; Lotze, M.T.; Yang, J.C.;Ann Surg,1989
2. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer;Clin Nephrol
3. Constant infusion recombinant interleukin-2 in adoptive immunotherapy ofadvanced cancer;West, W.H.; Tauer, K.W.; Yanelli, J.R.;NEnglJMed
4. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells;Denicoff, K.D.; Rubinow, D.R.; Papa, M.Z.;Ann Intern Med,1987
5. Extravasation of intravascular fluid mediated by the systemic administration of IL-2;Rosenstein, M.; Ettinghausen, S.E.; Rosenberg, S.A.;J Immunol